UKUK

100% premium: Novartis buys antibiotics specialists Neutec Pharma

21.07.2006

London – Another UK biotech company was taken over when Novartis signed a recommended all-cash offer worth Euro435 million for the antibiotics specialists Neutec pharma. The Swiss pharma giant paid more than twice of the Manchester-based company’s market capitalization before the takeover approach. Buying Neutec gives Novartis access to two advanced stage antibody products for serious hospital-acquired infections: Mycograb, for treating systemic fungal infections and Aurograb, for treating methicillin-resistant Staphylococcus aureus. Daniel Vasella, CEO of Novartis, said the products “promise to dramatically improve treatments in the area and will also enable Novartis to strengthen its biologics pipeline and anti-infective drug portfolio.” Mycograb has been filed in Europe and has been approved for compassionate use, while Aurograb is in phase III. NeuTec has retained 100% ownership of its products. The buyout is a big payday for the founders Ruth Mathews and James Burnie, who still own a 7% stake. During the takeover negotiations the founders secured NeuTecs operations at the current facility in Manchester for at least two years. The sale of the company came just three weeks after AstraZeneca agreed to buy Cambridge Antibody for Euro1.1 billion. Besides the Neutec deal the antibiotics market has seen amany known players disappear. One of the most prominent was the US-based Vicuron, bought by Pfizer for $1.9 billion. New companies have nevertheless emerged as Roche (Basilea), Sanofi-Aventis (Novexel), Sandoz (Nabriva) and Bayer (Aicuris) span out their infectious disease businesses.

Clinical Trial

28.03.2011

Belgian antibody-fragment specialist Ablynx NV (Ghent) initiated a Phase II study with its nanobody Alx-0061 in patients with rheumatoid arthritis (RA) at the end of March. Safety, pharmacokinetics and -dynamics of the nanobody,...

Politics / Law

25.03.2011

Luxembourg/Paris – The European Court of Justice (ECJ)is set to challenge the current GMO cultivation bans on Monsanto’s GM maize Mon810 in France, Luxembourg, Germany, Austria, Hungary, Bulgaria and Greece. This week, the...

Clinical Trial

23.03.2011

Dutch Mucosis BV (Groningen) has begun Phase I testing of its lead product, FluGEM™, an improved influenza vaccine for the elderly. Secondary endpoints will include mucosal and systemic immune responses, as well as correlates of...

Politics / Law

23.03.2011

London – For the first time, the European Medicines Agency (EMA) has opened its clinical trials register to the public. Certain protocol-related information on trials conducted in the EU are now available under...

Politics / Law

17.03.2011

Strasbourg – The strict scientific assessment of food health claims by the EU Food watchdog EFSA is going to be diluted by political intervention. Yesterday, the environment committee of the European Parliament recommended not to...

BioPeople

16.03.2011

French specialist for cell-based immunomodulation TxCell (Valbonne) has named Dr. François Meyer as its new CEO. Meyer brings the company more than 25 years of pharmaceutical and biotechnology experience. The appointment is an...

Politics / Law

16.03.2011

Brussels – After discussions on GMO policy with the EU Environment ministers at the week-end, the European Commission has left no doubt that it intends to adhere to the current central authorisation procedure and safety...

Politics / Law

11.03.2011

Luxembourg – Human cell cultures replacing animal toxicity testing, regenerative tissues or human disease cell models cannot be patented if they have been derived from human embryonic stem cells (hESCs), if the European Court...

Politics / Law

23.02.2011

Brussels – Europe has made the first step towards accepting inflow of not-EU approved GMOs in order to avoid disruption to EU animal feed supplies. On February 22th, a qualified majority of the Standing Committee of the Food...

Displaying results 181 to 190 out of 1983

< Previous 181-190 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/18/article/100-premium-novartis-buys-antibiotics-specialists-neutec-pharma.html

Events

All Events

Stock list

All quotes

TOP

  • BIOINVENT INTERNATIONAL AB (S)3.10 SEK9.15%
  • Allergy Therapeutics (UK)19.12 GBP6.94%
  • PHARMING (NL)0.48 EUR6.67%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • CHRONTECH PHARMA (S)0.07 SEK-12.50%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.55 CHF99.3%
  • ADDEX (CH)4.08 CHF85.5%

FLOP

  • MERCK KGAA (D)65.43 EUR-48.6%
  • HYBRIGENICS (F)1.83 EUR-29.1%
  • PROSENSA (NL)9.48 USD-26.2%

TOP

  • SANTHERA (CH)68.55 CHF3489.0%
  • GW PHARMACEUTICALS (UK)427.00 GBP780.4%
  • PAION (D)2.79 EUR304.3%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.48 USD-68.2%

No liability assumed, Date: 24.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products